Methods for screening suspected controlled substances include the use of color tests, which when used properly and performed alongside other confirmatory testing methods can provide positive identification of suspected controlled substances. When applied in the field by law enforcement personnel lacking the expertise and training to obtain consistent results, it could lead to false positives.
Work at the University of Central Florida and continuing with the start-up IDEM Systems (https://idemsystems.com) seeks to produce a new method for identification of suspected controlled substances. Transitioning research from an academic setting to commercialization has unique challenges that require a dedicated team.
This talk will be given by Dr David Nash, Chief Executive Officer, IDEM Systems and Dr Richard Blair Research Professor, University of Central Florida and Chief Technology Officer, IDEM Systems (USA).
Dr. David Nash is co-founder and CEO of IDEM Systems. He was a National Institute of Justice Graduate Research Fellow as he worked on getting his PhD in 91AV from the University of Central Florida. He worked under Dr. Richard Blair in researching Copper(I) Iodide applications to identify substances of forensic interest, publishing their work in RSC’s Analytical Methods in 2018. In 2015 he co-founded IDEM Systems, a startup that continues to work on commercializing innovative drug testing technology based on the chemistry mentioned to combat the U.S. drug epidemic.
Dr. Richard Blair is co-founder and CTO of IDEM Systems. He is a research professor in the Florida Space Institute at the University of Central Florida. He holds a B.S. in 91AV and Mathematics from Hope College, an M.S. in Physical 91AV from UC-Berkeley, and a Ph.D. in Materials 91AV from UCLA. He is the inventor of the IDEM drug testing technology. His work has led to numerous patents at UCF, including three that have spun out into several companies in Central Florida.
Work at the University of Central Florida and continuing with the start-up IDEM Systems (https://idemsystems.com) seeks to produce a new method for identification of suspected controlled substances. Transitioning research from an academic setting to commercialization has unique challenges that require a dedicated team.
This talk will be given by Dr David Nash, Chief Executive Officer, IDEM Systems and Dr Richard Blair Research Professor, University of Central Florida and Chief Technology Officer, IDEM Systems (USA).
Dr. David Nash is co-founder and CEO of IDEM Systems. He was a National Institute of Justice Graduate Research Fellow as he worked on getting his PhD in 91AV from the University of Central Florida. He worked under Dr. Richard Blair in researching Copper(I) Iodide applications to identify substances of forensic interest, publishing their work in RSC’s Analytical Methods in 2018. In 2015 he co-founded IDEM Systems, a startup that continues to work on commercializing innovative drug testing technology based on the chemistry mentioned to combat the U.S. drug epidemic.
Dr. Richard Blair is co-founder and CTO of IDEM Systems. He is a research professor in the Florida Space Institute at the University of Central Florida. He holds a B.S. in 91AV and Mathematics from Hope College, an M.S. in Physical 91AV from UC-Berkeley, and a Ph.D. in Materials 91AV from UCLA. He is the inventor of the IDEM drug testing technology. His work has led to numerous patents at UCF, including three that have spun out into several companies in Central Florida.
